Spectrum expects FDA ruling on Fusilev by April 29

Spectrum expects FDA ruling on Fusilev by April 29
(AP:IRVINE, Calif.) Federal regulators will review potential new uses for a drug from Spectrum Pharmaceuticals that is currently used to treat the side effects of a chemotherapy drug, the company said Monday.
Read more on INO News

Que. chemo patient calls for hair loss warning
A Montreal woman who has permanently lost all of the hair on her body says she was not warned about the possible side-effects of a popular chemotherapy drug.
Read more on CBC Ottawa

Texas Breast Specialists Adds Naviscan PEM Technology to Breast Cancer Treatment Services
Texas Breast Specialists, part of Texas Oncology, has expanded its breast cancer treatment services in Dallas, McKinney, Bedford, Carrollton, and Plano, Texas to include the mobile Naviscan PEM scanner.
Read more on PR Newswire via Yahoo! Finance